When Hims launched its men’s wellness platform in 2017 with a stripped-down telehealth model for finasteride and minoxidil, the pitch was disarmingly simple: skip the dermatologist, skip the awkward pharmacy run, get hair-loss medication delivered for the price of two coffees a week. Eight years later, the company reports roughly 2.3 million subscribers across its product categories, and Keeps — its closest direct competitor inside the same Hims & Hers portfolio — has scaled alongside it. The first wave of subscribers from 2017 and 2018 has now crossed the five-year mark, and a quieter conversation is starting to surface in dermatology offices, men’s health forums, and increasingly, in hair restoration consultations.
It is the conversation about what comes next.
According to data shared by the International Society of Hair Restoration Surgery (ISHRS) in its 2025 practice census, roughly 38 percent of first-time hair transplant patients in North America had been on a subscription telehealth regimen — Hims, Keeps, Roman, or a similar service — before booking surgery. Five years ago, that number was negligible because the category barely existed at scale. The pattern raises a financial and clinical question that subscribers in their thirties and early forties are starting to ask out loud: at what point does paying $40 to $90 a month, indefinitely, stop being the cheap option?
The Math That Nobody Runs Up Front
The case for telehealth finasteride is built around a low monthly entry price. The case against it, when subscribers actually do the arithmetic, is built around time.
A typical Hims hair plan in 2025 runs between $30 and $90 per month, depending on whether the subscriber takes oral finasteride alone, adds a topical minoxidil-finasteride spray, or layers in the company’s multivitamin and biotin gummies. Keeps follows a similar pricing structure. Most subscribers cluster in the $45 to $65 monthly band once they add the topical, which is the combination most telehealth prescribers recommend for visible regrowth on the crown.
Run that out over a realistic treatment horizon — because finasteride and minoxidil only work while they are being taken — and the numbers compound:
| Time horizon | Monthly spend $50 | Monthly spend $75 |
|—|—|—|
| 5 years | $3,000 | $4,500 |
| 10 years | $6,000 | $9,000 |
| 20 years | $12,000 | $18,000 |
| 30 years (to age 65 for a 35-year-old) | $18,000 | $27,000 |
A 35-year-old starting Hims today and continuing through his early sixties is signing up, in effect, for a five-figure recurring expense without ever owning the outcome. A hair transplant in Turkey at an established clinic — typically marketed as an all-inclusive package covering surgery, hotel, transfers, and aftercare — runs roughly $2,000 to $4,000 for a single session. The [turkey hair transplant cost](https://istanbul-care.com/hair-transplant-turkey-cost/) is the figure that subscribers tend to compare against year three or four of their subscription, not year one. By year ten, the subscription has cost two to three times what the surgery would have, and the medication still has to be taken.
That last point is the one most subscribers underestimate. Surgery does not replace finasteride for everyone; the transplanted hairs are permanent, but native hair behind and around the graft zone continues to thin without medical support. The honest comparison is not “drugs forever versus surgery once.” It is “drugs forever versus surgery plus a much smaller maintenance dose of drugs, often for a shorter window.”
Why Subscribers Plateau
The second reason the conversation is shifting has nothing to do with money. It has to do with what finasteride and minoxidil can and cannot do.
Finasteride works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), the androgen that miniaturizes follicles in genetically susceptible men. Clinical literature has been consistent for two decades: roughly 80 to 90 percent of men on 1 mg daily finasteride stop losing hair, and roughly 60 percent see some regrowth, primarily on the crown and mid-scalp. The hairline — the area men in their thirties care most about, photographically — is the area finasteride is weakest at restoring. Dermatologists describe this as the drug’s efficacy ceiling. It is real, it is well-documented, and it is the reason subscribers who started Hims at 32 with a maturing hairline often look at the mirror at 36 and conclude that the medication held the line on the crown but did not give them back the temples.
Minoxidil has its own ceiling and its own trap. The drug increases the proportion of follicles in the anagen (growth) phase, which produces visible thickening within four to six months. But the effect is dependent on continued use. Dermatology reviews report that roughly 30 percent of patients revert to their pre-treatment baseline within six months of stopping, and a smaller subset experience a sharp shed within weeks of cessation. Subscribers who pause their Keeps shipment during a move, a job change, or a stretch of travel often see the shed and re-subscribe in a state of mild panic. That experience — the realization that the bottle in the cabinet is now load-bearing — is what reframes the monthly charge in some subscribers’ minds. It stops feeling like a discretionary purchase and starts feeling like a tether.
Combined, the two drugs are genuinely effective for the right candidate. But “right candidate” tends to mean diffuse thinning on the crown in a man with intact temples. For Norwood III and above — receded corners, thinning vertex, established miniaturization at the front — telehealth medication is a holding pattern, not a solution.
The PFS Conversation
There is a third factor that subscribers rarely raise with the telehealth questionnaire but increasingly raise with surgeons, and it is the one most likely to push a long-term Hims user toward considering an alternative: post-finasteride syndrome.
PFS describes a cluster of persistent sexual, neurological, and mood-related side effects that some men report continuing after discontinuing finasteride. The U.S. Food and Drug Administration updated the Propecia label in 2012 to acknowledge reports of persistent erectile dysfunction after discontinuation, and added depression and suicidal ideation to the warnings in subsequent years. The clinical prevalence of true PFS — symptoms persisting more than three months after stopping the drug — remains contested in the literature, with estimates ranging from extremely rare (under 1 percent in industry-sponsored reviews) to materially higher in patient-reported registries. What is not contested is that a subset of long-term users either experience side effects acutely or worry about them chronically, and that worry shapes behavior.
For a 38-year-old who has been on daily finasteride for six years and is starting a family, the calculation around continuing indefinitely is no longer purely cosmetic. The question becomes whether there is a way to lock in the cosmetic gain — the hair he has now — without remaining on the drug at full dose for the rest of his fertile and pre-andropausal years. A hair transplant does not eliminate the question, because some native-hair maintenance is usually still recommended. But it changes the calculus: a topical formulation, a lower dose, or in some cases a planned taper becomes a clinically defensible path because the transplanted follicles are no longer DHT-sensitive and will hold their position regardless.
That conversation — about exit strategy from a daily systemic medication — is the one that telehealth platforms, by design, are not structured to have.
A Decision Framework Built Around Norwood Stage
Surgeons who consult with US-based patients in this demographic generally walk them through a framework that does not pit medication against surgery, but sequences them.
For **Norwood II to early III** — a maturing hairline, mild temple recession, no crown involvement — telehealth medication is almost always the right first move. The drugs work best on early, diffuse loss; surgery this early risks operating on follicles that have not yet declared themselves miniaturized. Subscribers in this category, typically men between 25 and 32, are spending their Hims dollars wisely.
For **Norwood III to IV** — established temple recession, beginning crown thinning, often the pattern at 33 to 42 — the picture is more complicated. Medication will likely stabilize the crown but will not reliably rebuild the temples. This is the band where the ISHRS data shows subscribers converting to first-time surgical candidates. A single 2,500 to 3,500 graft session typically addresses the frontal third and temples; medication continues as a maintenance therapy for the mid-scalp and crown. The combined approach tends to outperform either modality alone.
For **Norwood V and above** — significant loss across the front, mid, and crown — medication is largely a stabilizing measure. Surgery, often staged across two sessions, is the realistic path to coverage. Subscribers in this category who have been on Hims for several years frequently report that the medication “stopped working,” but a closer look usually reveals that it never could have done what they hoped at this stage of loss.
The framework does not produce a universal answer. It produces a personal one, anchored to a clinical examination and a candid conversation about what the patient is trying to accomplish over the next ten and twenty years rather than the next quarter.
Why Mid-Career US Men Look Abroad
The reason Turkey shows up in this calculation, specifically, is geographic clustering of specialization. Istanbul has become to hair restoration what Seoul has become to skincare and what certain Mexican border cities have become to dentistry: a dense market of clinics performing high volumes of a single procedure, with prices set by domestic competition rather than US healthcare overhead.
A [hair transplant in Turkey](https://istanbul-care.com/hair-transplant-turkey/) at a reputable clinic typically includes the surgical fee, anesthesia, a multi-night hotel stay, airport transfers, post-operative medication, and a follow-up protocol — for a total that lands between roughly $2,000 and $4,000 depending on graft count and clinic tier. The equivalent procedure at a private US clinic, billed per-graft at $4 to $8, often runs $12,000 to $25,000 before travel or recovery accommodation. For a salaried professional in his late thirties — the demographic core of the Hims subscriber base — the math is not subtle.
What mid-career US patients tend to scrutinize is not the price gap, which is obvious, but the quality controls underneath it. The questions that come up in consultation calls are about who performs the incisions versus the extractions, how many cases the operating surgeon handles per day, whether the clinic is JCI accredited or affiliated with a hospital, and what the revision or touch-up policy looks like if density at twelve months falls short of expectations. These are answerable questions, and the clinics that answer them transparently tend to be the ones that anchor the upper end of the Turkey market.
The travel itself, often cited as a deterrent, is typically a four to five day window: arrival, pre-op consultation, surgery, one to two recovery days, departure. Most patients return to desk-based work within seven to ten days of the procedure.
When Subscription Wins, When Surgery Wins
The honest version of this comparison ends without a winner.
Subscription telehealth wins when the patient is early, the loss is diffuse, the budget horizon is short, and the goal is stabilization. A 28-year-old with a maturing hairline who starts finasteride and minoxidil and stays on them through his thirties has made a defensible choice. The monthly charge is not the cheapest option in some abstract ten-year-NPV calculation, but it is the right clinical option for his stage, and that is what matters.
Surgery wins when the loss is established, the patient is in his mid-thirties or older, the cosmetic priority is the front of the scalp rather than the crown, and the patient is starting to chafe against the open-ended nature of the subscription model. The one-time cost — particularly at Turkey-market pricing — recovers itself against the cumulative subscription spend somewhere between year four and year six, and the cosmetic outcome addresses a zone the drugs were never going to fully rebuild.
The subscribers asking surgeons about this now are not, for the most part, disillusioned with Hims or Keeps. They are doing exactly what the platforms enabled them to do: take ownership of a medical decision that used to require a dermatology appointment they would not have booked. They are simply doing it again, with better information and a longer time horizon, five years into the relationship.
That, ultimately, is what the 2.3 million-subscriber number is starting to produce. Not a backlash. A maturation. The first generation of telehealth hair-loss patients is aging into the version of the decision that the monthly checkout flow was never designed to surface — and a quietly growing share of them are concluding, with a surgeon like [Surgeon Name] across a consultation table, that the right answer for year six is not the same as the right answer for year one.
